4//SEC Filing
Sucampo Pharmaceuticals, Inc. 4
Accession 0001171843-16-013440
CIK 0001365216operating
Filed
Nov 29, 7:00 PM ET
Accepted
Nov 30, 4:01 PM ET
Size
13.7 KB
Accession
0001171843-16-013440
Insider Transaction Report
Form 4
Getman Daniel P
Director
Transactions
- Exercise/Conversion
Employee Stock Option (right to buy)
2016-11-28−16,201→ 63,799 totalExercise: $6.80From: 2015-05-09Exp: 2024-05-09→ Class A Common Stock (16,201 underlying) - Sale
Common Stock, Class A
2016-11-28$16.89/sh−16,201$273,635→ 0 total - Exercise/Conversion
Common Stock, Class A
2016-11-28$6.80/sh+16,201$110,167→ 16,201 total - Exercise/Conversion
Common Stock, Class A
2016-11-29$6.80/sh+3,799$25,833→ 3,799 total - Sale
Common Stock, Class A
2016-11-29$16.75/sh−3,799$63,633→ 0 total - Exercise/Conversion
Employee Stock Option (right to buy)
2016-11-29−3,799→ 60,000 totalExercise: $6.80From: 2015-05-09Exp: 2024-05-09→ Class A Common Stock (3,799 underlying)
Footnotes (1)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.85 to $16.95, inclusive. The reporting person will, upon request, provide any security holder of Sucampo Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission full information regarding the number of shares sold at each separate price within the range.
Documents
Issuer
Sucampo Pharmaceuticals, Inc.
CIK 0001365216
Entity typeoperating
Related Parties
1- filerCIK 0001365216
Filing Metadata
- Form type
- 4
- Filed
- Nov 29, 7:00 PM ET
- Accepted
- Nov 30, 4:01 PM ET
- Size
- 13.7 KB